BRIEF-Ovid Therapeutics Announces Phase 1 Results For Ov350

Reuters12-18 21:33

BRIEF-Ovid <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Phase 1 Results For Ov350

Dec 18 (Reuters) - Ovid Therapeutics Inc OVID.O:

OVID THERAPEUTICS INC - ANNOUNCES PHASE 1 RESULTS FOR OV350
OVID THERAPEUTICS INC - OV350 SHOWS GOOD SAFETY PROFILE SUPPORTING KCC2 PORTFOLIO ADVANCEMENT
OVID THERAPEUTICS INC - NO TREATMENT-RELATED SAFETY FINDINGS OR SERIOUS ADVERSE EVENTS
OVID THERAPEUTICS INC - OV4071 ON TRACK FOR REGULATORY SUBMISSION FOR PHASE 1/1B CLINICAL TRIAL IN Q1 2026

Source text: ID:nGNX929Fn3

Further company coverage: OVID.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592909951?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-18 21:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592909951","market":"us","top_or_hot":-1,"title":"BRIEF-Ovid Therapeutics Announces Phase 1 Results For Ov350","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Phase 1 Results For Ov350</title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Ovid Therapeutics Inc <span>OVID.O</span>:</p><ul><li><p>OVID THERAPEUTICS INC - ANNOUNCES PHASE 1 RESULTS FOR OV350</p></li><li><p>OVID THERAPEUTICS INC - OV350 SHOWS GOOD SAFETY PROFILE SUPPORTING KCC2 PORTFOLIO ADVANCEMENT</p></li><li><p>OVID THERAPEUTICS INC - NO TREATMENT-RELATED SAFETY FINDINGS OR SERIOUS ADVERSE EVENTS</p></li><li><p>OVID THERAPEUTICS INC - OV4071 ON TRACK FOR REGULATORY SUBMISSION FOR PHASE 1/1B CLINICAL TRIAL IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX929Fn3</span></p><p>Further company coverage: <span>OVID.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Ovid Therapeutics Announces Phase 1 Results For Ov350</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Ovid Therapeutics Announces Phase 1 Results For Ov350\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-18 21:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Ovid <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Phase 1 Results For Ov350</title></head><body><p><span>Dec 18 (Reuters)</span><span> - </span>Ovid Therapeutics Inc <span>OVID.O</span>:</p><ul><li><p>OVID THERAPEUTICS INC - ANNOUNCES PHASE 1 RESULTS FOR OV350</p></li><li><p>OVID THERAPEUTICS INC - OV350 SHOWS GOOD SAFETY PROFILE SUPPORTING KCC2 PORTFOLIO ADVANCEMENT</p></li><li><p>OVID THERAPEUTICS INC - NO TREATMENT-RELATED SAFETY FINDINGS OR SERIOUS ADVERSE EVENTS</p></li><li><p>OVID THERAPEUTICS INC - OV4071 ON TRACK FOR REGULATORY SUBMISSION FOR PHASE 1/1B CLINICAL TRIAL IN Q1 2026</p></li></ul><p>Source text: <span>ID:nGNX929Fn3</span></p><p>Further company coverage: <span>OVID.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO0PX:1","article_id":"2592909951","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592909951","pubTimestamp":1766064817,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Ovid Therapeutics Announces Phase 1 Results For Ov350Dec 18 (Reuters) - Ovid Therapeutics Inc OVID.O:OVID THERAPEUTICS INC - ANNOUNCES PHASE 1 RESULTS FOR OV350OVID THERAPEUTICS INC - OV350 SHOW","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OVID":"Ovid Therapeutics Inc."},"translate_title":"简介-Ovid Therapeutics公布Ov350的1期结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OVID":0.9},"content_text":"BRIEF-Ovid Therapeutics Announces Phase 1 Results For Ov350Dec 18 (Reuters) - Ovid Therapeutics Inc OVID.O:OVID THERAPEUTICS INC - ANNOUNCES PHASE 1 RESULTS FOR OV350OVID THERAPEUTICS INC - OV350 SHOWS GOOD SAFETY PROFILE SUPPORTING KCC2 PORTFOLIO ADVANCEMENTOVID THERAPEUTICS INC - NO TREATMENT-RELATED SAFETY FINDINGS OR SERIOUS ADVERSE EVENTSOVID THERAPEUTICS INC - OV4071 ON TRACK FOR REGULATORY SUBMISSION FOR PHASE 1/1B CLINICAL TRIAL IN Q1 2026Source text: ID:nGNX929Fn3Further company coverage: OVID.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592909951","isCrawlerRequest":true}